Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy without an available effective systemic chemotherapy. Insulin growth factor 2 (IGF-2) overexpression leading to the activation of the IGF-1 receptor (IGF-1R)/mammalian target of rapamycin (mTOR) pathway is well...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, H X, Doyle, L A, Phan, A T, Habra, M A, Kurzrock, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590681/
https://www.ncbi.nlm.nih.gov/pubmed/23412108
http://dx.doi.org/10.1038/bjc.2013.46

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590681/
https://www.ncbi.nlm.nih.gov/pubmed/23412108
http://dx.doi.org/10.1038/bjc.2013.46

Ejemplares similares